ARGENX SE (ARGX)
About ARGENX SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $55.4B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $55.4B
- Shares outstanding
- 60.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 18, 2017
Argenx SE (ARGX) Stock Price
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARGENX SE.
Write a review
News about ARGENX SE
News & sentiment via Polygon.io
Argenx SE: frequently asked questions
Is Argenx SE an American company?
Argenx SE is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Argenx SE publicly traded?
Yes — Argenx SE is a publicly traded company. Its stock trades under the ticker symbol ARGX on the NASDAQ.
What does Argenx SE do?
Argenx SE is an American Pharmaceuticals company in the Health & Beauty sector.
